A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study

Nicolas Wentzensen, Ana Cecilia Rodriguez, Raphael Viscidi, Rolando Herrero, Allan Hildesheim, Arpita Ghosh, Jorge Morales, Sholom Wacholder, Diego Guillen, Mario Alfaro, Mahboobeh Safaeian, Robert D. Burk, Mark Schiffman

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background. A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. Methods. In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. Results. cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). Conclusions. Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalJournal of Infectious Diseases
Volume204
Issue number1
DOIs
StatePublished - Jul 1 2011

Fingerprint

Papillomavirus Infections
Adaptive Immunity
Natural History
Immunoassay
Virion
Enzyme-Linked Immunosorbent Assay
Odds Ratio
Seroepidemiologic Studies
Confidence Intervals
Infection
Immunity
Human papillomavirus 11
Human papillomavirus 6
Human papillomavirus 18
Sexual Partners
Neutralizing Antibodies
Cell Biology
Antibodies
DNA

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study. / Wentzensen, Nicolas; Rodriguez, Ana Cecilia; Viscidi, Raphael; Herrero, Rolando; Hildesheim, Allan; Ghosh, Arpita; Morales, Jorge; Wacholder, Sholom; Guillen, Diego; Alfaro, Mario; Safaeian, Mahboobeh; Burk, Robert D.; Schiffman, Mark.

In: Journal of Infectious Diseases, Vol. 204, No. 1, 01.07.2011, p. 94-102.

Research output: Contribution to journalArticle

Wentzensen, N, Rodriguez, AC, Viscidi, R, Herrero, R, Hildesheim, A, Ghosh, A, Morales, J, Wacholder, S, Guillen, D, Alfaro, M, Safaeian, M, Burk, RD & Schiffman, M 2011, 'A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study', Journal of Infectious Diseases, vol. 204, no. 1, pp. 94-102. https://doi.org/10.1093/infdis/jir209
Wentzensen, Nicolas ; Rodriguez, Ana Cecilia ; Viscidi, Raphael ; Herrero, Rolando ; Hildesheim, Allan ; Ghosh, Arpita ; Morales, Jorge ; Wacholder, Sholom ; Guillen, Diego ; Alfaro, Mario ; Safaeian, Mahboobeh ; Burk, Robert D. ; Schiffman, Mark. / A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study. In: Journal of Infectious Diseases. 2011 ; Vol. 204, No. 1. pp. 94-102.
@article{43b8195e946e4ac3b9a01f5037138caa,
title = "A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study",
abstract = "Background. A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. Methods. In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. Results. cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95{\%} confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95{\%} CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95{\%} CI, 0.15-0.94). Conclusions. Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.",
author = "Nicolas Wentzensen and Rodriguez, {Ana Cecilia} and Raphael Viscidi and Rolando Herrero and Allan Hildesheim and Arpita Ghosh and Jorge Morales and Sholom Wacholder and Diego Guillen and Mario Alfaro and Mahboobeh Safaeian and Burk, {Robert D.} and Mark Schiffman",
year = "2011",
month = "7",
day = "1",
doi = "10.1093/infdis/jir209",
language = "English (US)",
volume = "204",
pages = "94--102",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the guanacaste natural history study

AU - Wentzensen, Nicolas

AU - Rodriguez, Ana Cecilia

AU - Viscidi, Raphael

AU - Herrero, Rolando

AU - Hildesheim, Allan

AU - Ghosh, Arpita

AU - Morales, Jorge

AU - Wacholder, Sholom

AU - Guillen, Diego

AU - Alfaro, Mario

AU - Safaeian, Mahboobeh

AU - Burk, Robert D.

AU - Schiffman, Mark

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Background. A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. Methods. In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. Results. cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). Conclusions. Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.

AB - Background. A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18. Methods. In a cohort of 974 women from the Guanacaste Natural History Study, we studied the relationship of baseline cLIA and virus-like particle (VLP) enzyme-linked immunosorbent assay (ELISA) (HPV16 and HPV18 only) seropositivity to measures of HPV exposure, HPV DNA positivity, number of sexual partners, cytology findings, and age. We then studied immunity against subsequent infection with HPV6, 11, 16, 18 and related types over a 7-year period. Results. cLIA seroprevalence varied with previous exposure; the prevalence of cLIA results positive for HPV16 and HPV18 was lower than the prevalence of positive VLP ELISA responses. cLIA and VLP ELISA positivity predicted protection from subsequent infections with concordant types. The combined odds ratio for HPV16 and HPV18 cLIA positivity was 0.41 (95% confidence interval [CI], 0.21-0.80), and the combined odds ratio for the HPV16 and HPV18 VLP ELISA positivity was 0.65 (95% CI, 0.46-0.93). Of individual types, statistical significance was only reached for HPV16 cLIA positivity (odds ratio, 0.44; 95% CI, 0.15-0.94). Conclusions. Both assays showed an association between positive results and significant protection from subsequent infections for HPV16 and HPV18 combined. cLIA seroprevalence was lower than VLP ELISA, suggesting that the assay detects a subset of antibodies following natural infection that are specifically linked to immunity against subsequent HPV infection.

UR - http://www.scopus.com/inward/record.url?scp=79957953906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957953906&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir209

DO - 10.1093/infdis/jir209

M3 - Article

C2 - 21628663

AN - SCOPUS:79957953906

VL - 204

SP - 94

EP - 102

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -